The Children’s Oncology Group (COG) and Signify Health, Inc. have announced a partnership to facilitate clinical trial participation for pediatric patients through in-home clinical services.
Through this new collaboration, pediatric patients participating in COG Study AALL1731, a clinical trial for a therapy to treat B-cell acute lymphoblastic leukemia (B-ALL), now have expanded options to facilitate receipt of experimental treatment at home. AALL1731 (NCT03914625) is sponsored by the National Cancer Institute under a Cooperative Research and Development Agreement (CRADA) with Amgen and is currently open at 195 U.S. COG sites. This in-home infusion service is for the patients assigned to receive blinatumomab on AALL1731 who are unable to access outpatient pumps and homecare. Amgen has provided funding to NCI under the CRADA to support more pediatric patients to receive blinatumomab at home.
For more information, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.